SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-028162
Filing Date
2023-08-08
Accepted
2023-08-08 16:02:56
Documents
68
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20230630.htm   iXBRL 10-Q 1319479
2 EX-10.2 mrtx-2023630xex102.htm EX-10.2 25488
3 EX-10.3 mrtx-2023630xex103.htm EX-10.3 46175
4 EX-31.1 mrtx-2023630xex311.htm EX-31.1 12206
5 EX-31.2 mrtx-2023630xex312.htm EX-31.2 13311
6 EX-32.1 mrtx-2023630xex321.htm EX-32.1 7694
12 image_miratilogo.jpg GRAPHIC 11856
  Complete submission text file 0001628280-23-028162.txt   5958752

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20230630.xsd EX-101.SCH 41253
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20230630_cal.xml EX-101.CAL 65921
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20230630_def.xml EX-101.DEF 167204
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20230630_lab.xml EX-101.LAB 483006
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20230630_pre.xml EX-101.PRE 303625
62 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20230630_htm.xml XML 778959
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 231151102
SIC: 2834 Pharmaceutical Preparations